https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-82008-07-01 00:00:002019-02-15 09:19:26Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-3052008-07-01 00:00:002019-02-15 08:53:22Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-27 / BMC Immunol. 2008 Jun;9:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-27 / BMC Immunol. 2008 Jun;9:322008-06-27 00:00:002019-02-15 08:50:17Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-17 / J. Leukoc. Biol. 2008 Oct;84(4):981-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-17 / J. Leukoc. Biol. 2008 Oct;84(4):981-72008-06-17 00:00:002019-02-15 08:38:03The essential role of the in situ immune reaction in human colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-82008-06-16 00:00:002019-02-15 08:48:09Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-8072008-06-06 00:00:002008-06-06 00:00:00Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-802008-06-05 00:00:002021-11-15 17:04:06Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-72008-06-03 00:00:002021-11-15 17:04:28Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-01 / Gan To Kagaku Ryoho 2008 Jun;35(6):926-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-01 / Gan To Kagaku Ryoho 2008 Jun;35(6):926-302008-06-01 00:00:002019-02-15 08:59:42[Immunotherapy for glioma]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-01 / J. Immunother. 2008 Jun;31(5):458-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-01 / J. Immunother. 2008 Jun;31(5):458-652008-06-01 00:00:002019-02-15 09:19:27Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells
